Skip to content
value.today

Palvella Therapeutics, Inc.

PVLA
$2.2 Bmarket cap on Oct 29, 2026+11876.6% since Jan 2024
Compare
World rank
#6,081
Revenue
$29 M
For year ending December-2025
value.today research
Net income
$-37 M
-127.0% margin
value.today research
Employees
29
As of March 25, 2026
value.today research

Palvella Therapeutics, Inc. in brief

Palvella Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Massachusetts, USA. It was founded in 2000. Its market value was $2.2 B on 29 October 2026, which makes it the 6,081st largest listed company in the world and the 1,582nd largest in the USA on this site. In the year to December 2025 it had sales of $29 M and a net loss of $37 M. It employs about 29 people and Wesley H. Kaupinen is its chief executive. Its shares trade under the symbol PVLA (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Palvella Therapeutics, Inc.

On December 13, 2024, we completed the previously announced business combination with Legacy Palvella in accordance with the terms of the Merger Agreement, pursuant to which, among other matters, Merger Sub merged with and into Legacy Palvella, with Legacy Palvella surviving as our wholly owned subsidiary (such business combination, the Merger). In connection with the completion of the Merger, we changed our name from “Pieris Pharmaceuticals, Inc.” to “Palvella Therapeutics, Inc.,” and our business became primarily the business conducted by Legacy Palvella. We are now a clinical-stage biopharmaceutical company focused on developing and, if approved, commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies.

Palvella Therapeutics, Inc. timeline

6 events, 2000–2024
  1. 2000
  2. 🏁
    · approximate
    Founded
  3. 2013
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2014
  6. ✎
    Renamed Pieris Pharmaceuticals, Inc.
    Formerly Marika Inc..
  7. 2015
  8. 🔔
    Initial public offering as Pieris Pharmaceuticals, Inc.
    Final prospectus filed with the SEC on 30 June 2015; shares registered for exchange trading on 24 June 2015.
  9. 2019
  10. 💰
    Record revenue of $46 million
    FY2019, the highest of the 6 years on record.
  11. 2024
  12. ✎
    Renamed Palvella Therapeutics, Inc.
    Formerly Pieris Pharmaceuticals, Inc..

Events of Palvella Therapeutics, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$582 M$1.2 B$1.7 B$2.3 B2020202120222023202420252026

World rank over time

▲ up 9,822 places since 2020
2020-01-01: #15918#15,91820202021-01-01: #16708#16,70820212022-01-07: #17925#17,92520222022-12-25: #23593#23,59320222023-07-30: #29724#29,72420232024-01-05: #29221#29,22120242026-10-07: #6640#6,64020262026-10-29: #6096#6,0962026

Rank in USA: #3,239 (Jan 2020) · #3,451 (Jan 2021) · #3,664 (Jan 2022) · #4,568 (Dec 2022) · #5,223 (Jul 2023) · #4,392 (Jan 2024) · #1,677 (Oct 2026) · #1,583 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
73.6×
Price / book
77.0×
Free cash flow yield
-0.6%
Net margin
-127.0%
Operating margin
-131.7%
Return on equity
-133.0%
Liabilities / assets
53.0%
Revenue growth
+65.3%
R&D / revenue
20.5%
Revenue per employee
$1.0 M
Profit per employee
$-1.3 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $29M, net income $-27M$29MFY18Fiscal year ending Dec 2019: revenue $46M, net income $-25M$46MFY19Fiscal year ending Dec 2020: revenue $29M, net income $-37M$29MFY20Fiscal year ending Dec 2021: revenue $31M, net income $-46M$31MFY21Fiscal year ending Dec 2022: revenue $26M, net income $-33M$26MFY22Fiscal year ending Dec 2023: revenue $43M, net income $19M$43MFY23Fiscal year ending Dec 2024: revenue —, net income $-17M—FY24Fiscal year ending Dec 2025: revenue —, net income $-42M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-39M$-42M—
Dec 2024——$-14M$-17M—
Dec 2023$43M+65.3%$-12M$19M43.7%
Dec 2022$26M-17.6%$-43M$-33M-128.5%
Dec 2021$31M+7.2%$-52M$-46M-145.6%
Dec 2020$29M-36.6%$-34M$-37M-127.0%
Dec 2019$46M+59.0%$-27M$-25M-55.0%
Dec 2018$29M—$-31M$-27M-91.9%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-25M——$-3.71—
Dec 2024$-11M——$-7.83—
Dec 2023$-14M$0M$-14M$2.17—
Dec 2022$-60M$1M$-61M——
Dec 2021$-8M$1M$-9M$-0.71—
Dec 2020$-46M$3M$-49M$-0.68—
Dec 2019$-52M$2M$-55M$-0.56—
Dec 2018$-1M$2M$-3M$-0.50—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-4M—Dec ’24Three months to Mar 2025: revenue —, net income $-8M—Mar ’25Three months to Jun 2025: revenue —, net income $-9M—Jun ’25Three months to Sep 2025: revenue —, net income $-11M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-13M—Dec ’25Three months to Mar 2026: revenue —, net income $-16M—Mar ’26Three months to Jun 2026: revenue —, net income $-22M—Jun ’26Three months to Sep 2026: revenue —, net income $-25M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-25M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Palvella Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$29 M
Operating income
$-39 M
Net income
$-37 M

For year ending December-2025

Balance sheet

Total assets
$60 M
Total liabilities
$32 M
Total equity
$28 M

As of December-2025

Top 100 institutional investors in Palvella Therapeutics, Inc.#

As of Sep 30, 2026
199 institutions held 14.6 M shares (about 99.7% of the shares outstanding) on Sep 30, 2026. The ten largest hold 51.4%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Palvella Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Jennison Associates LLC1,101,652+141,033 (+14.68%)7.54%$152 MNov 16, 2026
2Montanova Capital, LLC1,044,898-90,508 (-7.97%)7.15%$144 MNov 16, 2026
3BlackRock, Inc.989,691+71,334 (+7.77%)6.77%$137 MNov 13, 2026
4Frazier Life Sciences Management, L.P.882,4000 (0.00%)6.04%$122 MNov 16, 2026
5First Light Asset Management, LLC734,086-37,815 (-4.90%)5.02%$101 MNov 16, 2026
6State Street Corp624,879-28,293 (-4.33%)4.27%$86 MNov 12, 2026
7BVF Inc/il607,149-65,640 (-9.76%)4.15%$84 MNov 16, 2026
8Price T Rowe Associates Inc /MD/591,995-46,873 (-7.34%)4.05%$82 MNov 16, 2026
9Vanguard Capital Management LLC540,712+26,918 (+5.24%)3.70%$75 MNov 13, 2026
10Westfield Capital Management Co LP396,045New2.71%$55 MNov 12, 2026
11Federated Hermes, Inc.332,422-100,593 (-23.23%)2.27%$46 MNov 12, 2026
12Marshall Wace, LLP329,799+326,947 (+11463.78%)2.26%$45 MNov 13, 2026
13Invesco Ltd.312,729+279,077 (+829.30%)2.14%$43 MNov 12, 2026
14Geode Capital Management, LLC311,596+35,432 (+12.83%)2.13%$43 MNov 6, 2026
15Frontier Capital Management Co LLC276,272-202,561 (-42.30%)1.89%$38 MNov 16, 2026
16Primecap Management Co/ca/268,609+12,427 (+4.85%)1.84%$37 MNov 12, 2026
17Alliancebernstein L.P.254,969+1,801 (+0.71%)1.74%$35 MNov 16, 2026
18Woodline Partners LP250,517-67,000 (-21.10%)1.71%$35 MNov 16, 2026
19Eventide Asset Management, LLC231,4840 (0.00%)1.58%$32 MNov 13, 2026
20Orbimed Advisors LLC229,860-62,500 (-21.38%)1.57%$32 MNov 16, 2026
21Emerald Advisers, LLC229,404-82 (-0.04%)1.57%$32 MNov 9, 2026
22Siren, L.L.C.207,485-50,000 (-19.42%)1.42%$29 MNov 12, 2026
23MPM Bioimpact LLC197,633-6,394 (-3.13%)1.35%$27 MNov 16, 2026
24William Blair Investment Management, LLC195,070New1.33%$27 MNov 6, 2026
25Bellevue Group AG155,0000 (0.00%)1.06%$21 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Palvella Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Goldman Sachs Group Inc151,841-49,673 (-24.65%)1.04%$21 MNov 16, 2026
27Morgan Stanley145,065-36,363 (-20.04%)0.99%$20 MNov 13, 2026
28Emerald Mutual Fund Advisers Trust142,111+12,264 (+9.44%)0.97%$20 MNov 9, 2026
29Vanguard Portfolio Management LLC135,246+6,284 (+4.87%)0.93%$19 MNov 13, 2026
30FMR LLC126,767-88,074 (-40.99%)0.87%$17 MNov 10, 2026
31UBS Group AG118,459+45,933 (+63.33%)0.81%$16 MNov 10, 2026
32First Turn Management, LLC109,871-46,579 (-29.77%)0.75%$15 MNov 16, 2026
33Charles Schwab Investment Management Inc108,609+76,026 (+233.33%)0.74%$15 MNov 16, 2026
34Northern Trust Corp107,062+9,869 (+10.15%)0.73%$15 MNov 16, 2026
35Lord, Abbett & Co. LLC87,087New0.60%$12 MNov 13, 2026
36Vanguard Fiduciary Trust Co86,774+12,779 (+17.27%)0.59%$12 MNov 13, 2026
37Clio Asset Management LLC86,012-331 (-0.38%)0.59%$12 MOct 13, 2026
38NEXTBio Capital Management LP80,409-9,500 (-10.57%)0.55%$11 MNov 13, 2026
39UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC70,033+2,564 (+3.80%)0.48%$10 MNov 16, 2026
40AWM Investment Company, Inc.69,4160 (0.00%)0.47%$10 MNov 13, 2026
41Bank Of America Corp /de/68,771+14,217 (+26.06%)0.47%$9 MNov 16, 2026
42Neuberger Berman Group LLC65,679-17,428 (-20.97%)0.45%$9 MNov 13, 2026
43Aberdeen Group plc63,347-56,891 (-47.32%)0.43%$9 MNov 10, 2026
44Seven Grand Managers, LLC60,0000 (0.00%)0.41%$8 MNov 16, 2026
45Clearbridge Investments, LLC59,240-101 (-0.17%)0.41%$8 MNov 12, 2026
46Nicholas Investment Partners, LP56,162+6,444 (+12.96%)0.38%$8 MNov 16, 2026
47Nan Fung Trinity (HK) LTD52,630New0.36%$7 MNov 6, 2026
48Royce & Associates LP50,509+10,000 (+24.69%)0.35%$7 MNov 9, 2026
49HSBC Holdings PLC50,0010 (0.00%)0.34%$7 MNov 16, 2026
50Silvercrest Asset Management Group LLC48,790+8,925 (+22.39%)0.33%$7 MNov 16, 2026
51Russell Investments Group, Ltd.47,892+25,547 (+114.33%)0.33%$7 MNov 6, 2026
52Ensign Peak Advisors, Inc45,359-6,301 (-12.20%)0.31%$6 MNov 12, 2026
53Lisanti Capital Growth, LLC41,990-985 (-2.29%)0.29%$6 MNov 5, 2026
54Renaissance Technologies LLC37,270-16,000 (-30.04%)0.26%$5 MNov 12, 2026
55WCM Investment Management, LLC36,406-3,734 (-9.30%)0.25%$5 MNov 10, 2026
56Bank of New York Mellon Corp33,172+2,585 (+8.45%)0.23%$5 MNov 5, 2026
57Mutual Of America Capital Management LLC31,074-244 (-0.78%)0.21%$4 MOct 23, 2026
58Nuveen, LLC28,612+3,381 (+13.40%)0.20%$4 MNov 10, 2026
59Quadrature Capital Ltd24,352New0.17%$3 MNov 13, 2026
60Blue Owl Capital Holdings LP23,003-13,256 (-36.56%)0.16%$3 MNov 13, 2026
61ACT Capital Partners, L.P.22,500—0.15%$3 MNov 6, 2026
62TD Asset Management Inc22,146-600 (-2.64%)0.15%$3 MNov 13, 2026
63Legato Capital Management LLC20,163-3,327 (-14.16%)0.14%$3 MNov 10, 2026
64Avidity Partners Management LP20,000-50,000 (-71.43%)0.14%$3 MNov 16, 2026
65Swiss National Bank19,4000 (0.00%)0.13%$3 MNov 12, 2026
66Fifth Third Bancorp19,211-16,374 (-46.01%)0.13%$3 MNov 5, 2026
67Millennium Management LLC19,147-33,065 (-63.33%)0.13%$3 MNov 16, 2026
68Alps Advisors Inc19,099+4,743 (+33.04%)0.13%$3 MNov 3, 2026
69Informed Momentum Co LLC19,056+207 (+1.10%)0.13%$3 MNov 16, 2026
70Wellington Management Group LLP18,848-16,746 (-47.05%)0.13%$3 MNov 16, 2026
71Manufacturers Life Insurance Company, The18,075+2,530 (+16.28%)0.12%$2 MNov 13, 2026
72F/m Investments LLC17,958+512 (+2.93%)0.12%$2 MNov 13, 2026
73XTX Topco Ltd17,327+8,466 (+95.54%)0.12%$2 MNov 16, 2026
74SEI Investments Co16,012+3,205 (+25.03%)0.11%$2 MNov 10, 2026
75Rafferty Asset Management, LLC15,725+4,364 (+38.41%)0.11%$2 MNov 13, 2026
76Rhumbline Advisers15,525+1,997 (+14.76%)0.11%$2 MNov 10, 2026
77iA Global Asset Management Inc.15,224New0.10%$2 MOct 29, 2026
78Atle Fund Management AB14,924New0.10%$2 MNov 12, 2026
79Calamos Advisors LLC13,361+2,882 (+27.50%)0.09%$2 MNov 2, 2026
80Jpmorgan Chase & Co12,551+4,131 (+49.06%)0.09%$2 MNov 12, 2026
81California State Teachers Retirement System12,525+1,363 (+12.21%)0.09%$2 MNov 13, 2026
82Oak Ridge Investments LLC12,454+416 (+3.46%)0.09%$2 MOct 30, 2026
83Deutsche Bank AG\11,662-176 (-1.49%)0.08%$2 MNov 6, 2026
84Cresset Asset Management, LLC11,6290 (0.00%)0.08%$2 MNov 16, 2026
85HRT Financial LP11,349New0.08%$2 MNov 13, 2026
86Mariner, LLC10,612+251 (+2.42%)0.07%$1 MNov 12, 2026
87Mitsubishi UFJ Asset Management (UK) Ltd.10,500+5,000 (+90.91%)0.07%$1 MOct 22, 2026
88Knights of Columbus Asset Advisors LLC10,078+47 (+0.47%)0.07%$1 MNov 5, 2026
89State Of Wisconsin Investment Board9,920+3,528 (+55.19%)0.07%$1 MNov 16, 2026
90Blackstone Inc.9,122New0.06%$1 MNov 16, 2026
91Citigroup Inc8,745-6,748 (-43.56%)0.06%$1 MNov 4, 2026
92Martingale Asset Management L P8,706+300 (+3.57%)0.06%$1 MNov 12, 2026
93Legal & General Group Plc8,061+67 (+0.84%)0.06%$1 MNov 16, 2026
94VANGUARD ASSET MANAGEMENT, Ltd7,837+1,438 (+22.47%)0.05%$1 MNov 13, 2026
95Exome Asset Management LLC7,809New0.05%$1 MNov 16, 2026
96Vanguard Global Advisers, LLC7,256+1,047 (+16.86%)0.05%$1 MNov 13, 2026
97MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.6,914+542 (+8.51%)0.05%$1 MNov 16, 2026
98Creative Planning6,913+2,786 (+67.51%)0.05%$1 MNov 2, 2026
99Wells Fargo & Company/mn6,621-6,387 (-49.10%)0.05%$1 MNov 16, 2026
100MetLife Investment Management, LLC6,576+171 (+2.67%)0.04%$1 MNov 16, 2026

All 199 institutional investors, with who bought and sold →

Mutual funds holding Palvella Therapeutics, Inc.#

163 funds hold shares worth $694 M (about 32.9% of the company). Since their previous reports 107 added shares and 29 sold, buying $131 M net.
Mutual funds holding Palvella Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc.408,678$62 M2.8%0.58%+49%Jun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.388,390$59 M2.7%<0.01%+7.4%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors281,586$43 M1.9%0.05%+49%Jun 30, 2026
🇺🇸 Federated Hermes Kaufmann FundFederated Advisory Services Company276,556$38 M1.9%0.78%no changeJul 31, 2026
🇺🇸 Eventide Healthcare & Life Sciences FundEventide Asset Management, LLC231,484$35 M1.6%2.0%no changeJun 30, 2026
🇺🇸 PGIM Jennison Small Company FundPrudential Jennison Small Co Fund, Inc.202,900$31 M1.4%0.89%+281%Jun 30, 2026
🇺🇸 PRIMECAP Odyssey Aggressive Growth FundPRIMECAP Management Company209,825$29 M1.4%0.39%+19%Jul 31, 2026
🇺🇸 T. Rowe Price New Horizons Fund, Inc.T. Rowe Price Associates, Inc.164,144$25 M1.1%0.17%+100%Jun 30, 2026
🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc.144,220$22 M0.99%0.18%−5.8%Jun 30, 2026
🇺🇸 PGIM Jennison Health Sciences FundPGIM INVESTMENTS LLC183,037$22 M1.3%1.6%no changeMay 29, 2026
🇺🇸 Federated Hermes Kaufmann Small Cap FundFederated Advisory Services Company150,500$21 M1.0%0.73%no changeJul 31, 2026
🇺🇸 Fidelity Small Cap Growth FundFidelity Management & Research Company LLC143,740$20 M0.98%0.23%+11%Jul 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.113,586$17 M0.78%0.02%+9.8%Jun 30, 2026
🇺🇸 AB Small Cap Growth PortfolioAllianceBernstein L.P.109,498$17 M0.75%0.53%−1.2%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC120,068$17 M0.82%0.05%+56%Jul 31, 2026
🇺🇸 T. Rowe Price Integrated U.S. Small-Cap Growth Equity FundT. Rowe Price Associates, Inc.105,729$16 M0.72%0.16%+126%Jun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors101,267$15 M0.69%0.10%+71%Jun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC92,731$13 M0.63%0.52%+29%Jul 31, 2026
🇺🇸 abrdn Healthcare Investorsabrdn Inc.79,433$12 M0.54%0.89%+45%Jun 30, 2026
🇺🇸 Fidelity Small Cap Growth K6 FundFidelity Management & Research Company LLC74,980$10 M0.51%0.23%+14%Jul 31, 2026
🇺🇸 ClearBridge Small Cap FundFRANKLIN TEMPLETON FUND ADVISER, LLC56,480$8 M0.39%1.1%no changeJul 31, 2026
🇺🇸 Emerald Growth FundRBB Fund, Inc.52,070$7 M0.36%0.49%—Jul 31, 2026
🇺🇸 Emerald Growth FundEmerald Mutual Fund Advisers Trust52,070$7 M0.36%0.47%—Apr 30, 2026
🇺🇸 abrdn Life Sciences Investorsabrdn Inc.40,805$6 M0.28%0.90%+55%Jun 30, 2026
🇺🇸 BlackRock Health Sciences Opportunities PortfolioBlackRock Advisors, LLC50,716$6 M0.35%0.10%newMay 29, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC47,929$6 M0.33%0.01%+19%May 31, 2026
🇺🇸 Calamos Timpani Small Cap Growth FundCalamos Advisors LLC39,054$5 M0.27%0.71%+22%Jul 31, 2026
🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc.36,632$5 M0.25%0.02%newJul 31, 2026
🇺🇸 Neuberger Small Cap Growth FundNeuberger Berman Investment Advisers LLC41,226$5 M0.28%0.70%+58%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.39,845$5 M0.27%0.03%+11%May 31, 2026
🇺🇸 Royce Smaller-Companies Growth FundRoyce & Associates, LP28,500$4 M0.19%1.8%+46%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.26,644$4 M0.18%0.05%+56%Jul 31, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.29,359$3 M0.20%0.02%+27%May 31, 2026
🇺🇸 Small Cap Core PortfolioAllianceBernstein L.P.21,576$3 M0.15%0.38%no changeJun 30, 2026
🇺🇸 BlackRock Health Sciences Term TrustBlackRock Advisors, LLC21,246$3 M0.15%0.30%no changeJun 30, 2026
🇺🇸 JNL Multi-Manager Small Cap Growth FundJackson National Asset Management, LLC20,998$3 M0.14%0.13%+1.2%Jun 30, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC20,508$3 M0.14%0.05%+73%Jun 30, 2026
🇺🇸 Invesco Health Care FundInvesco Advisers, Inc.20,783$3 M0.14%0.24%no changeJul 31, 2026
🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc.22,955$3 M0.16%0.15%+20%May 31, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors14,654$2 M0.10%<0.01%+32%Jun 30, 2026
🇺🇸 Moa Small Cap Value FundMUTUAL OF AMERICA CAPITAL MANAGEMENT LLC13,820$2 M0.09%0.51%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC17,334$2 M0.12%<0.01%+18%May 31, 2026
🇺🇸 F/m Emerald Life Sciences Innovation ETFRBB Fund, Inc.17,254$2 M0.12%1.9%—May 31, 2026
🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC16,700$2 M0.11%0.04%no changeMay 31, 2026
🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC13,887$2 M0.09%0.39%−12%Jul 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC13,674$2 M0.09%0.05%+47%Jul 31, 2026
🇺🇸 Invesco Dorsey Wright SmallCap Momentum ETFInvesco Capital Management LLC15,529$2 M0.11%0.44%−9.9%May 31, 2026
🇺🇸 Royce Small-Cap Trust, Inc.Royce & Associates, LP12,000$2 M0.08%0.07%no changeJun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC11,937$2 M0.08%0.05%+47%Jun 30, 2026
🇺🇸 T.Rowe Price Small Cap Growth PortfolioBrighthouse Investment Advisers, LLC11,869$2 M0.08%0.16%+95%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC14,105$2 M0.10%<0.01%+20%May 31, 2026
🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc.14,096$2 M0.10%1.0%+34%May 31, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC10,279$2 M0.07%0.10%+87%Jun 30, 2026
🇺🇸 PGIM Jennison Blend FundPGIM INVESTMENTS LLC12,791$2 M0.09%0.13%newMay 29, 2026
🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc.9,807$1 M0.07%0.20%+4.0%Jun 30, 2026
🇺🇸 Carillon Chartwell Small Cap FundCarillon Tower Advisers, Inc.9,733$1 M0.07%0.59%+4.5%Jun 30, 2026
🇺🇸 M Capital Appreciation FundNorthern Lights Fund Trust II9,387$1 M0.06%0.45%—Jun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC10,185$1 M0.07%<0.01%no changeJul 31, 2026
🇺🇸 Victory Small Cap Stock FundVictory Capital Management Inc.9,944$1 M0.07%0.14%no changeJul 31, 2026
🇺🇸 Calamos Growth FundCalamos Advisors LLC9,197$1 M0.06%0.07%+9.9%Jul 31, 2026
🇺🇸 Knights of Columbus Small Cap Equity FundKnights of Columbus Asset Advisors LLC9,159$1 M0.06%0.60%+32%Jul 31, 2026
🇺🇸 T. Rowe Price Integrated U.S. Small-Mid Cap Core Equity FundT. Rowe Price Associates, Inc.8,208$1 M0.06%0.06%+135%Jun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC7,890$1 M0.05%0.03%+49%Jun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation7,800$1 M0.05%0.05%+59%Jun 30, 2026
🇺🇸 M Capital Appreciation FundM Financial Investment Advisers, Inc.9,479$1 M0.06%0.45%—Mar 31, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC8,482$1 M0.06%0.12%+176%Jul 31, 2026
🇺🇸 Transamerica T. Rowe Price Small Cap VPTransamerica Asset Management, Inc.7,634$1 M0.05%0.16%+108%Jun 30, 2026
🇺🇸 Nicholas Partners Small Cap Growth FundNicholas Investment Partners, L.P.7,426$1 M0.05%0.59%+39%Jun 30, 2026
🇺🇸 Carillon Chartwell Small Cap Growth FundCarillon Tower Advisers, Inc.7,147$1 M0.05%0.56%+24%Jun 30, 2026
🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc.6,555$1 M0.04%0.06%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC6,500$1 M0.04%0.05%+65%Jun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.6,227$1 M0.04%<0.01%−3.6%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC7,742$1 M0.05%<0.01%no changeMay 31, 2026
🇺🇸 Federated Hermes Kaufmann Fund IIFederated Advisory Services Company5,959$1 M0.04%0.81%—Jun 30, 2026
🇺🇸 Alger Small Cap Growth PortfolioFred Alger Management, LLC5,769$1 M0.04%0.54%no changeJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.5,621$1 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.5,550$1 M0.04%0.05%+59%Jun 30, 2026
🇺🇸 AVIP AB Small Cap PortfolioCONSTELLATION INVESTMENTS INC5,531$1 M0.04%0.27%−8.6%Jun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.5,926$1 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.6,763$1 M0.05%0.05%+9.1%May 31, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC5,426$1 M0.04%<0.01%+14%Jul 31, 2026
🇺🇸 LVIP Franklin Templeton Multi-Factor SMID Cap Equity FundLincoln Financial Investments Corporation4,831$1 M0.03%0.07%+4.0%Jun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC5,240$1 M0.04%0.05%+57%Jul 31, 2026
🇺🇸 BlackRock Health Sciences TrustBlackRock Advisors, LLC4,480$1 M0.03%0.12%no changeJun 30, 2026
🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC4,864$1 M0.03%0.02%+8.2%Jul 31, 2026
🇺🇸 Biotechnology Ultrasector ProfundProFund Advisors LLC4,860$1 M0.03%0.34%—Apr 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC3,940$1 M0.03%0.03%+57%Jun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC3,631$1 M0.02%0.05%+41%Jun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.3,600$1 M0.02%0.02%+33%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC3,451$1 M0.02%0.05%+52%Jun 30, 2026
🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors3,332$1 M0.02%<0.01%+71%Jun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC3,654$1 M0.02%0.02%+12%Jul 31, 2026
🇺🇸 PACE Small/Medium Co Growth Equity InvestmentsUBS Asset Management (Americas) LLC3,499$0 M0.02%0.19%+14%Jul 31, 2026
🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC3,173$0 M0.02%0.19%−5.9%Jun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC3,154$0 M0.02%0.05%+55%Jun 30, 2026
🇺🇸 Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGoldman Sachs Asset Management, L.P.4,017$0 M0.03%0.05%+1.4%May 31, 2026
🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds3,096$0 M0.02%0.06%newJun 30, 2026
🇺🇸 Health Sciences PortfolioPacific Life Fund Advisors LLC3,008$0 M0.02%0.12%no changeJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index ETFFidelity Management & Research Company LLC3,843$0 M0.03%<0.01%−14%May 31, 2026
🇺🇸 Voya MI Dynamic SMID Cap FundVoya Investments, LLC3,599$0 M0.02%0.30%newMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Palvella Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$850 K
3 purchases, 2 insiders
Sold, 12 months
$15.6 M
74 sales, 4 insiders
Net, 12 months
-$14.7 M
open market only
Insiders on file
22
since
$800 K-$4.9 M$0Aug 2024: bought $92 K (4 trades), sold $0 (0 trades)Aug 24Dec 2024: bought $52 K (1 trades), sold $0 (0 trades)Apr 2025: bought $101 K (2 trades), sold $0 (0 trades)AprNov 2025: bought $0 (0 trades), sold $371 K (2 trades)Dec 2025: bought $0 (0 trades), sold $415 K (1 trades)DecJan 2026: bought $0 (0 trades), sold $420 K (2 trades)Feb 2026: bought $800 K (2 trades), sold $342 K (2 trades)FebMar 2026: bought $50 K (1 trades), sold $508 K (3 trades)Apr 2026: bought $0 (0 trades), sold $547 K (5 trades)AprMay 2026: bought $0 (0 trades), sold $476 K (3 trades)Jun 2026: bought $0 (0 trades), sold $476 K (3 trades)JunJul 2026: bought $0 (0 trades), sold $642 K (4 trades)Aug 2026: bought $0 (0 trades), sold $655 K (5 trades)AugSep 2026: bought $0 (0 trades), sold $4.9 M (13 trades)Oct 2026: bought $0 (0 trades), sold $4.1 M (20 trades)OctNov 2026: bought $0 (0 trades), sold $2.1 M (13 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Palvella Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Jeffrey S. MartiniChief Scientific OfficerOption exercise10b5-1 plan+6,250$9.790$61 K6,250Form 4
filed Jeffrey S. MartiniChief Scientific OfficerSell10b5-1 plan-1,650$164.14$271 K4,600Form 4
filed Jeffrey S. MartiniChief Scientific OfficerSell10b5-1 plan-1,467$165.78$243 K3,133Form 4
filed Jeffrey S. MartiniChief Scientific OfficerSell10b5-1 plan-1,133$166.76$189 K2,000Form 4
filed Jeffrey S. MartiniChief Scientific OfficerSell10b5-1 plan-1,200$167.75$201 K800Form 4
filed Jeffrey S. MartiniChief Scientific OfficerSell10b5-1 plan-600$168.73$101 K200Form 4
filed Jeffrey S. MartiniChief Scientific OfficerSell10b5-1 plan-200$169.78$34 K0Form 4
filed Jeffrey S. MartiniChief Scientific OfficerOption exercise10b5-1 plan+4,266$7.530$32 K4,266Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Palvella Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
2.6 M
21.0% of shares · 11.46 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 2.273-for-1 split

Fails to deliver

  • : 1,164 shares at $147.47
  • : 24,390 shares at $132.91
  • : 4,080 shares at $122.58
  • : 3 shares at $128.00
  • : 862 shares at $158.13

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Palvella Therapeutics, Inc. scorecard#

Passes 1 of the 13 checks that could be worked out. Fiscal year 2025; market cap of Oct 29, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median77.0×Price to book 77.0× against Biotechnology's median of 2.9×.
    • ✗Price to sales below its peers' median73.6×Price to sales 73.6× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-0.6%Free cash flow is -0.6% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-3.71 vs -7.83Diluted EPS -3.71 in fiscal 2025 against -7.83 the year before (report's currency).
    • ✗Net income higher than five years earlier-$42 M-$42 M in fiscal 2025 against -$37 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$42 MNet income -$42 M in fiscal 2025.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-92.1%-92.1% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities5.2×Current ratio 5.20 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year405.4%Diluted shares up 405.4% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Palvella Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Palvella Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue——432631294629255.8r
Research and development238.28.8r53674755412220r
General and administrative165.93.1r1617171818188.9r
Operating expenses391412r69836373604029r
Operating income−39−14−12r−43−52−34−27−31−15−23r
Interest expense and finance costs00.40———————
Net interest income2.60.6————————
Other non-operating income (expense)0.7−0.1r0.7r1.32.4−3.7−0.01.8−2.10.1r
Income before tax−42−1719r−33−46−37−25−27−17−23r
Income tax000000.20−0.31.10.2r
Net income attributable to shareholders−42−1719r−33−46−37−25−27−18−23r
Earnings per share, basic-3.71-7.832.19r-0.45-0.71-0.68-0.56-0.50-0.40-0.55
Earnings per share, diluted-3.71-7.832.17—-0.71-0.68-0.56-0.50-0.40-0.55
Shares, weighted average (basic)112.21.8r746554————
Shares, weighted average (diluted)112.21.8—655451534442r
Balance sheet
Cash and cash equivalents58847.4r391187062753829r
Short-term investments0—9.021004253350
Receivables00.40r5.83.31.76.82.7160.1r
Other current assets1.02.30.2r3.2r6.53.64.14.61.63.3r
Current assets59887.5r73128761151359033r
Property, plant and equipment——0171922205.04.02.3r
Right-of-use (leased) assets0.60—3.73.93.93.40——
Long-term investments———————09.90
Total assets60887.5r9515410514114110435r
Accounts payable4.64.60.9r4.28.61.85.83.42.52.4r
Current liabilities11122.4r3751222748468.4r
Lease liabilities (non-current)0.400121416150——
Total liabilities322611r681037490101929.8r
Retained earnings−135−94−76r−290−257−211−174−147−120−103r
Shareholders' equity2863−74r−94r513151401225r
Total liabilities and equity60887.5r9515410514114110435r
Shares outstanding12111.8r75725655544543
Cash-flow statement
Depreciation and amortization——1.92.82.5—————
Share-based compensation6.40.80.6r4.45.25.15.44.93.01.9r
Cash from operating activities−25−11−14r−60−7.7−46−52−1.150−14r
Capital expenditure——−0.2−1.0−0.9−2.7−2.5−1.7−2.0−0.6r
Cash from investing activities——12−21−0.9399.8−8.9−46−0.6r
Shares issued——206.9389.6————
Cash from financing activities−0.7875.0r7.2591032494.115r
Exchange-rate effect on cash0.00.0——−3.24.7−2.1−1.6——
Change in cash−2676−8.7r−79478.2−13378.50.0r
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Palvella Therapeutics, Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 2 subsidiaries on file.

Present: offices, subsidiaries, branches or revenue (2 countries)Nothing on fileDots mark countries too small to see. Hover, tap or tab to a country for its figures.
Palvella Therapeutics, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office1 subsidiary—
🇩🇪 Germany1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Palvella Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$3.4 M
Wesley H. Kaupinen
Other top executives, average
$2.0 M
the CEO earned 1.7× this
$100 invested is now
$126
Palvella Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Wesley H. Kaupinen$3.4 M$57.1 M$2.0 M$126
2024Wesley H. Kaupinen$5.1 M$4.6 M$1.2 M$14
2023Wesley H. Kaupinen$1.4 M$554 K$717 K$18

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Palvella Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 3 · Material agreement 1 · Shareholder vote 2 · Results announced 9

Palvella Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Directors and officers8-K
Directors and officersShareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 5, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Palvella Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2019$32 MPrivate placement after listing$10 to $50 million9equity, optionsSEC
Jun 2016$17 MPrivate placement after listing$10 to $50 million15equity, optionsSEC
Dec 2014$40 MIssued in a merger or acquisition$10 to $50 million21equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Palvella Therapeutics, Inc.#

2 labor condition applications certified in fiscal 2025 for 2 positions, at a median wage of $128 K a year.

Certified, FY2025
2
#1,622 among companies on value.today
Worker positions
2
Median wage offered
$128 K
a year, full-time
Applications filed
2
Palvella Therapeutics, Inc.: most frequent H-1B job titles in fiscal 2025
Job titlePositionsMedian wage offered
Analytical Development ScientistChemists2$128 K

Where: Wayne, PA 2

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Palvella Therapeutics, Inc.

Layoffs at Palvella Therapeutics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2023–2023
Latest
—
2023-07-17
Palvella Therapeutics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2023············—
Palvella Therapeutics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
70% of workforceRestructuring planSEC 8-K“In connection therewith, on July 17, 2023, the Board of Directors of the Company approved a reduction in force of the Company's workforce by approximately 70% to be substantially c…”Filing
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

Discuss Palvella Therapeutics, Inc.#

3 automatic updates and 0 member comments. Sign in to comment and react.

  • Results announced on 5 November 2026automatic update · Nov 5, 2026

    Palvella Therapeutics, Inc. announced results on 5 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $25 million.

  • Insider trading in October 2026automatic update · Oct 31, 2026

    Directors and officers of Palvella Therapeutics, Inc. reported open-market trades for October 2026 (SEC Forms 4 and 5): 2 insiders sold shares worth about $4,116,784 in 20 trades. Awards, option exercises and shares withheld for tax are not counted.

  • Mutual funds: 163 funds hold $694 millionautomatic update · Jul 31, 2026

    163 mutual funds in 1 country hold shares of Palvella Therapeutics, Inc. worth $694 million, about 32.9% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 107 funds added shares and 29 sold; on balance they bought $131 million. Share splits are not counted as trading.

How Palvella Therapeutics, Inc. compares in Biotechnology

  • Market cap$2.2 B · higher than 81% of 726
  • Revenue$29 M · higher than 53% of 647
  • Net margin-127.0% · higher than 39% of 408
  • Revenue growth65.3% · higher than 78% of 438
  • Price / sales73.6× · lower than 14% of 339
  • Price / book77.0× · lower than 2% of 534
  • FCF yield-0.6% · higher than 85% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Palvella Therapeutics, Inc.🇺🇸$2.2 B—-127.0%+65.3%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 29, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of March 25, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, value.today research, GLEIF register, SEC filing.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Palvella Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Palvella Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Palvella Therapeutics, Inc.? Suggest a correction